Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SK Bio To Go All The Way With Novel Epilepsy Drug

This article was originally published in PharmAsia News

Executive Summary

SK Biopharmaceuticals, the new drug development subsidiary of South Korean conglomerate SK Group, is to seek approval of epilepsy drug YKP3089 without conducting a Phase III efficacy trial and aims to launch the drug globally in 2018, becoming the first domestic pharma to develop, commercialize and market a new product single handedly.


Related Content

LG Restructuring Ups Group Emphasis On ‘Red Biotech’


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts